Drug Retention Rates and Treatment Discontinuation among Anti-TNF-α Agents in Psoriatic Arthritis and Ankylosing Spondylitis in Clinical Practice
Objective. The study aim was to determine treatment persistence rates and to identify causes of discontinuation in psoriatic arthritis (PsA) and ankylosing spondylitis (AS) patients in clinical practice. Methods. Patients treated with adalimumab (ADA), etanercept (ETA), or infliximab (INF) were retr...
Saved in:
Main Authors: | Marta Fabbroni (Author), Luca Cantarini (Author), Francesco Caso (Author), Luisa Costa (Author), Veronica Anna Pagano (Author), Bruno Frediani (Author), Stefania Manganelli (Author), Mauro Galeazzi (Author) |
---|---|
Format: | Book |
Published: |
Hindawi Limited,
2014-01-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Recommendations for starting anti TNF-α in patients with ankylosing spondylitis
by: L. Olivieri, et al.
Published: (2003) -
Secukinumab for ankylosing spondylitis and psoriatic arthritis
by: Lubrano E, et al.
Published: (2016) -
Predictive factors for partial remission according to the Ankylosing Spondylitis Assessment Study working group in patients with ankylosing spondylitis treated with anti-TNFα drugs
by: F.M. Perrotta, et al.
Published: (2014) -
Persistence of secukinumab in patients with psoriasis, psoriatic arthritis, and ankylosing spondylitis
by: Elena Conesa-Nicolás, et al.
Published: (2021) -
TNF-alpha antagonists for treatment of juvenile ankylosing spondylitis
by: Kiss EV, et al.
Published: (2011)